Delcath Systems, Inc

At close
No trades
See on super-charts

Key stats

Market capitalization
48.625MUSD
Dividends yield (FY)
Price to earnings Ratio (TTM)
Basic EPS (TTM)
−3.79USD

About Delcath Systems, Inc

ISIN
US24661P8077
CEO
Gerard J. Michel
Headquarters
New York
Employees
55
Founded
1988

Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. It develops and commercializes CHEMOSAT and Melphalan Hydrochloride for Injection, which is a proprietary product used with the Delcath Hepatic Delivery System. The company was founded in August 1988 and is headquartered in New York, NY.

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:
‪0‬
Revenue
‪0‬

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more